EFFECTS OF ANGIOTENSIN RECEPTOR ANTAGONIST ON CHRONIC NEPHROPATY IN KIDNEY TRANSPLANTED PATIENTS. A PILOT STUDY.

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2004-001673-25-IT

Enrollment

Unknown

Registered

2005-06-22

Start date

2004-07-30

Completion date

Unknown

Last updated

2021-10-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

CHRONIC NEPHROPATY REDUCTION MedDRA version: 6.1 Level: SOC Classification code 10038359

Interventions

Trade Name: TAREG 80*80 MG 28 CPS Pharmaceutical Form: Capsule, hard INN or Proposed INN: Valsartan CAS Number: 137862-53-4 Concentration unit: mg milligram(s) Concentration type: equal Concentration

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Main Objective: ;Secondary Objective: ;Primary end point(s):	—

Countries

Italy

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026